Leeds’ St James’s Institute of Oncology Acquires Two Elekta Versa HD Radiotherapy Systems

Revolutionary technology enables higher quality cancer care for patients in
Yorkshire
LEEDS, England, May 27 – St James's Institute of Oncology, a leading
radiotherapy center in the UK, recently ordered two Versa HD™ systems, an
advanced linear accelerator designed to improve patient care and treat a wide
range of tumors throughout the body. As the latest, most sophisticated cancer
treatment system on the market, Versa HD can help maximize health care
resources. The system can deliver conventional therapies to a wide range of
tumors throughout the body, while also permitting treatment of complex cancers
that require extreme targeting accuracy.

St James’s investigators performed extensive clinical studies with High Dose
Rate mode and Elekta’s 160-leaf multileaf collimator (Agility™), both critical
components of Versa HD. Agility provides exceptional conformance of the
radiation beam to the tumor, avoiding healthy tissue. In addition, the unique
combination of Agility – with its rapid leaf speeds – and High Dose Rate mode
enables rapid delivery of the radiation dose, enabling faster treatments. In
their clinical studies of these integrated technologies, St James’s researchers
achieved substantial reductions in treatment times.

“These early experiences with Agility and High Dose Rate mode formed our
decision to acquire two Versa HD systems at the earliest opportunity,” says
Vivian Cosgrove, Ph.D., Head of Radiotherapy Physics at St James’s.

St James’s first Versa HD will be ready to treat patients in July 2013, with the
second system operational by the end of the year.

Lung and prostate cancers targeted
St James’s clinicians foresee an important role for Versa HD in the treatment of
inoperable lung cancer. The clinic has used hypofractionated lung stereotactic
radiation therapy (SRT) since 2009, employing its Elekta technology extensively
for these patients. Now, with Versa HD, St James’s hopes to exploit the system’s
speed to further limit the likelihood of patient movement during treatment,
thereby improving the accuracy and safety of SRT.

For its Versa HD systems, St James’s will prioritize the treatment of these
inoperable lung cancer patients, in addition to those with prostate cancer.

“We are managing a heavy workload of more than 7,000 new radiotherapy patients
per year,” says Kevin Franks, M.D., Consultant in Clinical Oncology at St
James’s. “The Versa HD systems will definitely enhance our treatment efficiency.
In fact, we have an ambitious plan to treat over 60 patients per day on the
first Versa HD installed in our department. Our initial experience indicates
this is achievable”.

“In addition to minimizing risk of irradiating healthy tissue, we also decrease
treatment times, making it a much better experience for the patient,” he adds.
“Moreover, by reducing treatment times, we should be able to add more patients
to the daily schedule, which will increase access to this technology for
patients in Leeds and throughout Yorkshire.”

For more information, visit www.VersaHD.com.

Versa HD is not for sale or distribution in all markets.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on May 27, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.